Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma

Adenocarcinoma

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Adenocarcinoma, Clear Cell

Adenomyoepithelioma

Carcinoma, Endometrioid

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Endometrial Neoplasms

Uterine Neoplasms

Ovarian Cancer

Ovarian Epithelial Cancer

Epithelial-myoepithelial Carcinoma

Subjects will be treated with NXP800 at 50 mg/day.

Subjects will be treated with NXP800 at 75 mg/day.

NXP800 is an anti-neoplastic, oral small molecule.

NXP800

Diane Marsolini

Shay Shemesh, MSc

Alexandrea Cronin

Kassie DiOrio

Melissa Barnes

Ashley Douglas, RN, BSN, OCN

Ruth Orr

Udai Banerji, Prof

Susana Banerjee, Dr

The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.

Part A of the study is a dose escalation by cohort study of NXP800 administered to patients with advanced cancers. The study will identify the maximum tolerated dose (MTD) and propose dose and dose schedules for future studies.

In Part B doses selected in Part A are administered to patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

Part A dose escalation followed by Part B, expansion in ovarian cancers.

Part B is enrolling ovarian cancer patients.

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

European Network of Gynaecological Oncological Trial Groups (ENGOT)

GOG Foundation

Nuvectis Pharma, Inc.

Spots Global Cancer Trial Database for nxp800

Every month we try and update this database with for nxp800 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for nxp800

Every month we try and update this database with for nxp800 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for nxp800 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.